Completed PHASE4 INTERVENTIONAL 3-arm NCT00084136

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings (PEARLS)

Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Conditions HIV Infections

Interventions Atazanavir Didanosine (enteric-coated) Efavirenz Emtricitabine Emtricitabine/Tenofovir disoproxil fumarate Lamivudine/Zidovudine

Updated 8 times since 2017 Last updated: Sep 11, 2018 Started: May 31, 2005 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on HIV Infections, this trial is completed. The trial is conducted by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections and has accumulated 8 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jun 2024 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jun 2024 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Nov 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Nov 2018 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

AIDS Research Unit P.O. Box A178, Zimbabwe , Barranco, Peru , Bicentenaire, Haiti , Chapel Hill, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Dallas, United States , Denver, United States , Durban, South Africa and 23 more locations